Brief: Allarity Therapeutics And US Veteran’S Administration Open Enrollment For Mid-Stage Trial Of Stenoparib With Temozolomide In Relapsed Small Cell Lung Cancer
03/02/2026 13:20
Feb 3 (Reuters) - Allarity Therapeutics Inc ALLR.O: ALLARITY THERAPEUTICS ANNOUNCES THAT ITS COLLABORATIVE PHASE 2 TRIAL WITH THE UNITED STATES VETERAN’S ADMINISTRATION COMBINING STENOPARIB WITH TEMOZOLOMIDE IN RELAPSED SMALL CELL LUNG CANCER IS NOW OPEN FOR ENROLLMENT Source text: ID:nGNX4SWTgn Further company coverage: ALLR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic